The system is designed for users seeking to make side-by-side comparisons between cell cultures, run long-term experiments, and monitor cells while working remotely.
CytoSMART Technologies’ CytoSMART Multi Lux, a new automated live-cell imaging system, helps laboratory teams conduct long-term experiment runs and comparison studies and is useful for large teams.
The system is designed for users seeking to make side-by-side comparisons between cell cultures, run long-term experiments, and monitor cells from home while working remotely. The CytoSMART Multi Lux comes equipped with four sample stages for side-by-side comparison, label-free image analysis, and full remote access.
“An advanced live-cell imaging system consisting of four mini digital microscopes supported by automated image analysis software is especially useful for research groups that have been negatively impacted by COVID-19 restrictions and want to find new ways to continue their research,” said Joffry Maltha, CEO at CytoSMART Technologies, in a Sept. 10, 2020 company press release. “No matter how big your laboratory team is, this new Multi Lux technology lets scientists run up to four experiments simultaneously from inside the incubator at perfect culture conditions. Automated image analysis and immediate visualization of the results are accessible remotely via the CytoSMART Cloud. Besides, researchers who need to culture cells for weeks or even months, can also benefit from this long-term live-cell imaging solution without fear of needing to throw away cells because of failed experiments.”
The company launched the new product in September 2020.
Source: CytoSMART
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.